4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes

4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes

Copyright © 2010 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 137(2010), 2 vom: 02. Nov., Seite 221-33
1. Verfasser: Sluijter, B J R (VerfasserIn)
Weitere Verfasser: van den Hout, M F C M, Stam, A G M, Lougheed, S M, Suhoski, M M, van den Eertwegh, A J M, van den Tol, M P, van Leeuwen, P A M, Meijer, S, Scheper, R J, June, C H, de Gruijl, T D, Santegoets, S J A M
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2010
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article 4-1BB Ligand Antibodies, Monoclonal Antigens, CD Epitopes, T-Lymphocyte Interleukins Lysosomal-Associated Membrane Protein 1 Melanoma-Specific Antigens Oligodeoxyribonucleotides ProMune mehr... Receptors, IgG TNFRSF9 protein, human Tumor Necrosis Factor Receptor Superfamily, Member 9 Tumor Necrosis Factor-alpha Interferon-gamma 82115-62-6
LEADER 01000caa a22002652 4500
001 NLM200308289
003 DE-627
005 20250211211338.0
007 cr uuu---uuuuu
008 231223s2010 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2010.07.009  |2 doi 
028 5 2 |a pubmed25n0668.xml 
035 |a (DE-627)NLM200308289 
035 |a (NLM)20708974 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Sluijter, B J R  |e verfasserin  |4 aut 
245 1 0 |a 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes 
264 1 |c 2010 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 17.02.2011 
500 |a Date Revised 15.12.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2010 Elsevier Inc. All rights reserved. 
520 |a We have been studying the re-activation of tumor-associated antigen (TAA)-specific CD8(+) T cells in sentinel lymph nodes (SLN) of melanoma patients upon intradermal administration of the CpG-B oligodeoxynucleotide PF-3512676. To facilitate functional testing of T cells from small SLN samples, high-efficiency polyclonal T cell expansion is required. In this study, SLN cells were expanded via classic methodologies with plate- or bead-bound anti-CD3/CD28 antibodies and with the K562/CD32/4-1BBL artificial APC system (K32/4-1BBL aAPC) and analyzed for responsiveness to common recall or TAA-derived peptides. K32/4-1BBL-expanded T cell populations contained significantly more effector/memory CD8(+) T cells. Moreover, recall and melanoma antigen-specific CD8(+) T cells were more frequently detected in K32/4-1BBL-expanded samples as compared with anti-CD3/CD28-expanded samples. We conclude that K32/4-1BBL aAPC are superior to anti-CD3/CD28 antibodies for the expansion of in vivo-primed specific CD8(+) T cells and that their use facilitates the sensitive monitoring of functional anti-tumor T cell immunity in SLN 
650 4 |a Journal Article 
650 7 |a 4-1BB Ligand  |2 NLM 
650 7 |a Antibodies, Monoclonal  |2 NLM 
650 7 |a Antigens, CD  |2 NLM 
650 7 |a Epitopes, T-Lymphocyte  |2 NLM 
650 7 |a Interleukins  |2 NLM 
650 7 |a Lysosomal-Associated Membrane Protein 1  |2 NLM 
650 7 |a Melanoma-Specific Antigens  |2 NLM 
650 7 |a Oligodeoxyribonucleotides  |2 NLM 
650 7 |a ProMune  |2 NLM 
650 7 |a Receptors, IgG  |2 NLM 
650 7 |a TNFRSF9 protein, human  |2 NLM 
650 7 |a Tumor Necrosis Factor Receptor Superfamily, Member 9  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
700 1 |a van den Hout, M F C M  |e verfasserin  |4 aut 
700 1 |a Stam, A G M  |e verfasserin  |4 aut 
700 1 |a Lougheed, S M  |e verfasserin  |4 aut 
700 1 |a Suhoski, M M  |e verfasserin  |4 aut 
700 1 |a van den Eertwegh, A J M  |e verfasserin  |4 aut 
700 1 |a van den Tol, M P  |e verfasserin  |4 aut 
700 1 |a van Leeuwen, P A M  |e verfasserin  |4 aut 
700 1 |a Meijer, S  |e verfasserin  |4 aut 
700 1 |a Scheper, R J  |e verfasserin  |4 aut 
700 1 |a June, C H  |e verfasserin  |4 aut 
700 1 |a de Gruijl, T D  |e verfasserin  |4 aut 
700 1 |a Santegoets, S J A M  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 137(2010), 2 vom: 02. Nov., Seite 221-33  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:137  |g year:2010  |g number:2  |g day:02  |g month:11  |g pages:221-33 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2010.07.009  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 137  |j 2010  |e 2  |b 02  |c 11  |h 221-33